Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants. Participants will receive a single dose of miricorilant under fed conditions with a standard breakfast after an overnight fast alone and in combination with once-daily doses of fluvoxamine. Blood samples will be collected at regular intervals for PK and safety analysis between admission and discharge from the clinical unit.

Inclusion Criteria:Able to understand a written informed consentWilling and able to comply with all study requirements including potential CYP 2C19 genotyping analysisMale participants must agree to use an adequate method of contraceptionHealthy men or non-pregnant, non-lactating healthy women of non-childbearing potentialBody mass index of 19.0 to 32.0 kg/m^2Body weight ≥50 kg.Exclusion Criteria:Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipientsPresence or history of clinically significant allergy requiring treatment. Hay fever is allowed unless it is active.Significant skin disease, including rash, food allergy, eczema, psoriasis, or urticariaHistory of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease (except cholecystectomy), bleeding disorder, neurological or psychiatric disorder, as judged by the InvestigatorPoor venous access that limits phlebotomyEvidence of current SARS-CoV-2 infectionClinically significant abnormal clinical chemistry, hematology, or urinalysis as judged by the Investigator. Participants with Gilbert's Syndrome are allowed.Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody resultsEvidence of renal impairment at screeningPositive highly sensitive serum pregnancy test at screening or admission. Those who are pregnant or lactating will be excluded. A woman is considered of childbearing potential unless she is permanently sterile or is postmenopausal.Clinically-significant ECG abnormalities or vital sign abnormalities at screening or at baselineHave received any study drug in a clinical research study within 30 days (or 5 half-lives if longer) prior to first dose of study medicationAre taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 2 g per day acetaminophen or COVID-19 vaccines) in the 14 days before study drug administration. Exceptions may apply.Are currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months, or 3 months for inhaled productsAre taking, or have taken, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors within 3 months before study drug administrationHistory of any drug or alcohol abuse in the past 2 yearsRegular alcohol consumption in men >21 units per week and women >14 units per week (1 unit = 12 oz 1 bottle/can of beer, 1 oz 40% spirit, or 5 oz glass of wine)Confirmed positive alcohol urine test at screening or admissionCurrent smokers and those who have smoked within the last 12 monthsCurrent users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 monthsPositive drugs of abuse test resultMale participants with pregnant or lactating partnersDonation of blood within 2 months or donation of plasma within 7 days prior to first dose of study medicationAre, or are immediate family members of a study site or Sponsor employeeFailure to satisfy the investigator of fitness to participate for any other reason.